Literature DB >> 29222269

Current treatment of double hit and double expressor lymphoma.

Patrick M Reagan1, Andrew Davies2.   

Abstract

A 60-year-old female presented with abdominal pain and distension. Following computed tomography scans of the abdomen and pelvis, she was taken urgently to the operating room, with the belief that she had appendicitis with perforation. At laparotomy, the findings were consistent with an ovarian carcinoma; there was extensive infiltration of the ovary, bowel, and omental deposits. Cytoreductive surgery was performed including total abdominal hysterectomy and bilateral salpingo-oophorectomy. The final pathology, however, revealed infiltration with medium-sized atypical lymphoid cells positive for CD20, CD10, MYC, BLC2, and BCL6 by immunohistochemistry. MYC and BCL2 translocations were identified by fluorescence in situ hybridization consistent with a diagnosis of high-grade B-cell lymphoma with rearrangements of MYC and BCL2 With the current data available, what is the optimal treatment of this patient?
© 2016 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29222269      PMCID: PMC6142550          DOI: 10.1182/asheducation-2017.1.295

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  10 in total

1.  MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation.

Authors:  Wendy Cuccuini; Josette Briere; Nicolas Mounier; Hans-Ullrich Voelker; Andreas Rosenwald; Christer Sundstrom; Sergio Cogliatti; Edouard Hirchaud; Loic Ysebaert; Dominique Bron; Jean Soulier; Philippe Gaulard; Remi Houlgatte; Christian Gisselbrecht; Catherine Thieblemont
Journal:  Blood       Date:  2012-03-09       Impact factor: 22.113

Review 2.  Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis.

Authors:  Christina Howlett; Sonya J Snedecor; Daniel J Landsburg; Jakub Svoboda; Elise A Chong; Stephen J Schuster; Sunita Dwivedy Nasta; Tatyana Feldman; Allison Rago; Kristy M Walsh; Scott Weber; Andre Goy; Anthony Mato
Journal:  Br J Haematol       Date:  2015-04-24       Impact factor: 6.998

3.  Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.

Authors:  Daniel J Landsburg; Marissa K Falkiewicz; Joseph Maly; Kristie A Blum; Christina Howlett; Tatyana Feldman; Anthony R Mato; Brian T Hill; Shaoying Li; L Jeffrey Medeiros; Pallawi Torka; Francisco Hernandez-Ilizaliturri; Nishitha M Reddy; Arun Singavi; Timothy S Fenske; Julio C Chavez; Jason B Kaplan; Amir Behdad; Adam M Petrich; Martin A Bast; Julie M Vose; Adam J Olszewski; Cristiana Costa; Frederick Lansigan; James N Gerson; Stefan K Barta; Oscar Calzada; Jonathon B Cohen; Jennifer K Lue; Jennifer E Amengual; Xavier Rivera; Daniel O Persky; David J Peace; Sunita Nathan; Ryan D Cassaday
Journal:  J Clin Oncol       Date:  2017-05-05       Impact factor: 44.544

4.  Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.

Authors:  Alex F Herrera; Matthew Mei; Lawrence Low; Haesook T Kim; Gabriel K Griffin; Joo Y Song; Reid W Merryman; Victoria Bedell; Christine Pak; Heather Sun; Tanya Paris; Tracey Stiller; Jennifer R Brown; Lihua E Budde; Wing C Chan; Robert Chen; Matthew S Davids; Arnold S Freedman; David C Fisher; Eric D Jacobsen; Caron A Jacobson; Ann S LaCasce; Joyce Murata-Collins; Auayporn P Nademanee; Joycelynne M Palmer; German A Pihan; Raju Pillai; Leslie Popplewell; Tanya Siddiqi; Aliyah R Sohani; Jasmine Zain; Steven T Rosen; Larry W Kwak; David M Weinstock; Stephen J Forman; Dennis D Weisenburger; Young Kim; Scott J Rodig; Amrita Krishnan; Philippe Armand
Journal:  J Clin Oncol       Date:  2016-10-24       Impact factor: 44.544

5.  Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.

Authors:  Nathalie A Johnson; Kerry J Savage; Olga Ludkovski; Susana Ben-Neriah; Ryan Woods; Christian Steidl; Martin J S Dyer; Reiner Siebert; John Kuruvilla; Richard Klasa; Joseph M Connors; Randy D Gascoyne; Douglas E Horsman
Journal:  Blood       Date:  2009-07-13       Impact factor: 22.113

6.  High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial.

Authors:  Andrés J M Ferreri; Giovanni Donadoni; Maria Giuseppina Cabras; Caterina Patti; Michael Mian; Renato Zambello; Corrado Tarella; Massimo Di Nicola; Alfonso M D'Arco; Gianluca Doa; Marta Bruno-Ventre; Andrea Assanelli; Marco Foppoli; Giovanni Citterio; Alessandro Fanni; Antonino Mulè; Federico Caligaris-Cappio; Fabio Ciceri
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

7.  MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.

Authors:  Shimin Hu; Zijun Y Xu-Monette; Alexander Tzankov; Tina Green; Lin Wu; Aarthi Balasubramanyam; Wei-min Liu; Carlo Visco; Yong Li; Roberto N Miranda; Santiago Montes-Moreno; Karen Dybkaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; Xiaoying Zhao; J Han van Krieken; Qin Huang; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; Fan Zhou; Graham W Slack; Randy D Gascoyne; Meifeng Tu; Daina Variakojis; Weina Chen; Ronald S Go; Miguel A Piris; Michael B Møller; L Jeffrey Medeiros; Ken H Young
Journal:  Blood       Date:  2013-02-28       Impact factor: 22.113

8.  Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.

Authors:  Adam M Petrich; Mitul Gandhi; Borko Jovanovic; Jorge J Castillo; Saurabh Rajguru; David T Yang; Khushboo A Shah; Jeremy D Whyman; Frederick Lansigan; Francisco J Hernandez-Ilizaliturri; Lisa X Lee; Stefan K Barta; Shruthi Melinamani; Reem Karmali; Camille Adeimy; Scott Smith; Neil Dalal; Chadi Nabhan; David Peace; Julie Vose; Andrew M Evens; Namrata Shah; Timothy S Fenske; Andrew D Zelenetz; Daniel J Landsburg; Christina Howlett; Anthony Mato; Michael Jaglal; Julio C Chavez; Judy P Tsai; Nishitha Reddy; Shaoying Li; Caitlin Handler; Christopher R Flowers; Jonathon B Cohen; Kristie A Blum; Kevin Song; Haowei Linda Sun; Oliver Press; Ryan Cassaday; Jesse Jaso; L Jeffrey Medeiros; Aliyah R Sohani; Jeremy S Abramson
Journal:  Blood       Date:  2014-08-26       Impact factor: 22.113

9.  Double hit lymphoma: the MD Anderson Cancer Center clinical experience.

Authors:  Yasuhiro Oki; Mansoor Noorani; Pei Lin; Richard E Davis; Sattva S Neelapu; Long Ma; Mohamed Ahmed; Maria Alma Rodriguez; Fredrick B Hagemeister; Nathan Fowler; Michael Wang; Michelle A Fanale; Loretta Nastoupil; Felipe Samaniego; Hun J Lee; Bouthaina S Dabaja; Chelsea C Pinnix; Leonard J Medeiros; Yago Nieto; Issa Khouri; Larry W Kwak; Francesco Turturro; Jorge E Romaguera; Luis E Fayad; Jason R Westin
Journal:  Br J Haematol       Date:  2014-06-18       Impact factor: 6.998

10.  CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP.

Authors:  Norbert Schmitz; Samira Zeynalova; Maike Nickelsen; Roopesh Kansara; Diego Villa; Laurie H Sehn; Bertram Glass; David W Scott; Randy D Gascoyne; Joseph M Connors; Marita Ziepert; Michael Pfreundschuh; Markus Loeffler; Kerry J Savage
Journal:  J Clin Oncol       Date:  2016-07-05       Impact factor: 44.544

  10 in total
  7 in total

1.  BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models.

Authors:  Xiaohong Zhao; Yuan Ren; Matthew Lawlor; Bijal D Shah; Paul M C Park; Tint Lwin; Xuefeng Wang; Kenian Liu; Michelle Wang; Jing Gao; Tao Li; Mousheng Xu; Ariosto S Silva; Kaplan Lee; Tinghu Zhang; John M Koomen; Huijuan Jiang; Praneeth R Sudalagunta; Mark B Meads; Fengdong Cheng; Chengfeng Bi; Kai Fu; Huitao Fan; William S Dalton; Lynn C Moscinski; Kenneth H Shain; Eduardo M Sotomayor; Gang Greg Wang; Nathanael S Gray; John L Cleveland; Jun Qi; Jianguo Tao
Journal:  Cancer Cell       Date:  2019-05-13       Impact factor: 31.743

Review 2.  New Insights into Diffuse Large B-Cell Lymphoma Pathobiology.

Authors:  Antonio Giovanni Solimando; Tiziana Annese; Roberto Tamma; Giuseppe Ingravallo; Eugenio Maiorano; Angelo Vacca; Giorgina Specchia; Domenico Ribatti
Journal:  Cancers (Basel)       Date:  2020-07-11       Impact factor: 6.639

3.  C-MYC and BCL2: Correlation between Protein Over-Expression and Gene Translocation and Impact on Outcome in Diffuse Large B Cell Lymphoma

Authors:  Amrallah A Mohammed; Hayam E Rashed; Aziza E Abdelrahman; Ahmed A Obaya; Mostafa Toam; Hanim M Abdel Nour; Mohamed I Abdelhamid; Fifi Mostafa Elsayed
Journal:  Asian Pac J Cancer Prev       Date:  2019-05-25

Review 4.  Drug therapy for double-hit lymphoma.

Authors:  Vania Phuoc; Jose Sandoval-Sus; Julio C Chavez
Journal:  Drugs Context       Date:  2019-12-02

5.  Upregulation of fatty acid synthase in MYC and BCL-2 double-expressor lymphoma.

Authors:  Xing Zhong; Zhiliang Liu; Qingfeng Luo; Jingao Li; Weiwei Zhang; Yuerong Shuang
Journal:  Oncol Lett       Date:  2021-02-02       Impact factor: 2.967

6.  R-split-EPOCH plus high dose methotrexate in untreated diffuse large B cell lymphoma with MYC rearrangement or double expression of MYC and BCL-2.

Authors:  Peng Sun; Yu Wang; Cui Chen; Hang Yang; Man Nie; Xiao-Qing Sun; Xiao-Hua He; Wen-Qi Jiang; Zhi-Ming Li
Journal:  J Cancer       Date:  2021-02-02       Impact factor: 4.207

7.  Double-Expressor Appendiceal Burkitt's Lymphoma: A Case Report and Literature Review.

Authors:  Osama N Dukmak; Hamzeh M I Abugharbieh; Mohammad Farid Emar; Iman Khamayseh; Salem M Tos; Rafiq Salhab
Journal:  Case Rep Hematol       Date:  2022-03-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.